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 ONCOLOGY
Multidrug chemotherapy causes early 
radiological signs of loosening in distal 
femoral replacements
Aims
Limb salvage in bone tumour patients replaces the bone with massive segmental prostheses 
where achieving bone integration at the shoulder of the implant through extracortical bone 
growth has been shown to prevent loosening. This study investigates the effect of multidrug 
chemotherapy on extracortical bone growth and early radiological signs of aseptic loosen-
ing in patients with massive distal femoral prostheses.
Methods
A retrospective radiological analysis was performed on adult patients with distal femoral 
arthroplasties. In all, 16 patients were included in the chemotherapy group with 18 patients 
in the non- chemotherapy control group. Annual radiographs were analyzed for three years 
postoperatively. Dimensions of the bony pedicle, osseointegration of the hydroxyapatite 
(HA) collar surface, bone resorption at the implant shoulder, and radiolucent line (RLL) for-
mation around the cemented component were analyzed.
Results
A greater RLL score (p = 0.041) was observed at three years postoperatively, with those 
receiving chemotherapy showing greater radiological loosening compared with those not 
receiving chemotherapy. Chemotherapy patients experience osteolysis at the shoulder 
of the ingrowth collar over time (p < 0.001) compared with non- chemotherapy patients 
where osteolysis was not observed. A greater median percentage integration of the collar 
surface was observed in the non- chemotherapy group (8.6%, interquartile range (IQR) 
0.0% to 37.9%; p = 0.021) at three years. Bone growth around the collar was observed in 
both groups, and no statistical difference in amount of extracortical bony bridging was 
seen.
Conclusion
Multidrug chemotherapy affects the osseointegration of ingrowth collars and accelerates 
signs of radiological loosening. This may increase the risk of aseptic loosening in patients 
with massive segmental implants used to treat bone cancer.
Cite this article: Bone Joint Res 2020;9(7):333–340.
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Article focus
 Investigating the effect of multidrug 
chemotherapy on early radiological signs 
of aseptic loosening in patients with 
massive distal femoral endoprostheses.
Key messages
 Multidrug chemotherapy signifi-
cantly affects osseointegration of 
ingrowth collars and accelerates aseptic 
loosening of distal femoral endopros-
theses appearing as early as three years 
postoperatively.
 The authors of this paper recommend 
that bone tumour units provide stringent 
follow- up to those patients receiving 
chemotherapy, particularly in the initial 
years postoperatively.
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Strengths and limitations
 This is the first adequately powered study to inves-
tigate the effect of multidrug chemotherapy on 
osseointegration.
 Surgery was carried out by a number of orthopaedic 
surgeons specializing in treating bone cancers. Pres-
ervation of the periosteum at the shoulder of the 
implant was not recorded.
 A limitation of the study is that this was a retrospec-
tive study design with small numbers.
Introduction
Studies have shown that the introduction of an adjuvant 
chemotherapy regime improves the survivorship of malig-
nant bone tumour patients.1,2 Prior to this amputation 
was the standard treatment, however improving patient 
mortality rates shifted focus to limb salvage involving 
segmental resection of the tumour with reconstruction 
using endoprostheses. Although custom endoprostheses 
require time for manufacture that may delay chemo-
therapy and worsen prognosis, Rosen et al3 demon-
strated that the use of neoadjuvant chemotherapy where 
patients were treated preoperatively while fabricating 
the custom endoprosthesis was beneficial. Currently, 
approximately 80% of osteosarcoma patients are treated 
with neoadjuvant chemotherapy and limb salvage.4
Although chemotherapy has significantly lowered 
the risk of metastatic disease, complications from recon-
structive techniques continue to result in late morbidity. 
According to Jeys et al,5 aseptic loosening is the most 
common reason for failure of endoprostheses and 
accounts for 28.6% of failures. Implant fixation requires 
the bone to be healthy and viable. Literature has shown 
there to be substantial effects of doxorubicin, cisplatin, 
and ifosfamide on osteotomy healing and incorporation 
of cortical autografts.6 For bone tumour implants, extra-
cortical bony- bridging (ECBB) where bone forms over the 
implant shaft and stabilizes the fixation has been shown 
to reduce loosening.7 Coathup et al8 showed that 98% of 
distal femoral arthroplasties (DFRs) survive to ten years 
if their hydroxyapatite (HA) collar had osseointegrated 
compared to 75% if they had not. Radiologically, aseptic 
loosening around segmental implants initially mani-
fests itself with the development of a ‘gap’ of localized 
cortical bone loss at the bone- shoulder implant junction. 
Over time, as osteolysis increases, there is progression 
of periprosthetic bone- cement radiolucent lines that 
advance along the interface eventually leading to aseptic 
loosening.9
This study investigates the effect of multidrug chemo-
therapy on extracortical bone growth and early radio-
logical signs of loosening around massive distal femoral 
bone tumour prostheses. We hypothesized that patients 
undergoing chemotherapy would show less osseointe-
gration of their endoprosthesis with greater loosening 
compared to patients who did not receive chemotherapy.
Methods
Study design and setting. A retrospective case- control 
study was conducted. No patient or animal contact was 
involved in this study and therefore ethical approval was 
not required. A database of all DFRs (Stanmore Implants, 
Elstree, UK) performed in our unit between 2004 and 
2013 was collated. Annual radiographs for the first three 
postoperative years were analyzed using the local Picture 
Archiving and Communication System (PACS; Centricity; 
GE Healthcare, Amersham, UK). Demographic data as 
well as diagnosis and resection level were recorded for 
each patient with the extracortical bone growth, osseo-
integration, gap at transection site, and radiolucent line 
score (RLL) measured on each radiograph.
Patients. Adult patients who had undergone reconstruc-
tion using DFRs with HA ingrowth collars were includ-
ed in our study. The custom DFRs were all based on the 
Stanmore Modular Individualized Lower Limb System 
(SMILES) rotating hinge knee arthroplasty (Stanmore 
Implants). The most significant difference between the 
implants used for individual patients is the length of 
proximal implant shaft as this is dictated by the resection 
level. They all used the HA collar on the shaft and initial 
fixation was achieved using a cemented intramedullary 
stem proximally and distally. The chemotherapy group 
consisted of patients who were diagnosed with primary 
bone tumours (Table  I). The non- chemotherapy control 
group consisted of patients who were diagnosed with 
giant cell tumours. All the procedures were performed 
in one institution and no patients were recalled for the 
purposes of this study.
The selection criteria were chosen in particular to 
exclude cases where the potential for bone growth and 
osseointegration was not biased between the groups. 
Patients aged less than 16 years at the time of surgery, 
patients with an underlying diagnosis of rheumatoid 
arthritis, patients who had received radiotherapy directly 
to or near the transection site,11 patients who received 
DFRs used in reconstruction for metastatic lesions,12 and 
patients who received DFRs used in revision procedures 
were all excluded. Patients who developed a prosthetic 
infection were excluded even if this was diagnosed 
beyond the first three postoperative years, as it was 
assumed the implant was infected beforehand.
A total of 302 patients were identified using a local 
database. In all, 216 of these patients were excluded 
according to our criteria, leaving 86 potentially eligible 
patients. Overall, 24 patients were allocated to the chemo-
therapy group with 62 in the non- chemotherapy group. 
Further exclusions were made based on the quality of the 
radiographs (Figure 1). This left 16 eligible patients in the 
chemotherapy group and 18 in the non- chemotherapy 
group who had radiographs at one, two, and three years. 
Demographic data as well as resection level (%) and RLL 
scores are summarized in Table II. 
Variables, outcome measures, data sources, and 
bias. Radiological analysis was performed by one 
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observer (TCE). Anteroposterior (AP) and lateral (L) 
radiographs were used to quantify all measurements 
(Figure 2). Resection level was defined by the proportion 
of the femur that had been resected, taken from the joint 
line to the transection site, expressed as a percentage of the 
total length of the femur. The amount of extracortical bone 
Table I. Patients included in chemotherapy group with chemotherapy regimen.
Case no. Diagnosis Chemotherapy Agents
1 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
2 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
3 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate with maintenance 
pegylated interferon*
4 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
5 High grade pleomorphic sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin
6 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
7 High grade spindle cell sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin
8 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
9 Ewing’s sarcoma Neoadjuvant and adjuvant VIDE (neoadjuvant), VAI (adjuvant)†
10 High grade pleomorphic sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin
11 High grade spindle cell sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin
12 Ewing’s sarcoma Neoadjuvant and adjuvant VIDE (neoadjuvant), VAC (adjuvant)‡
13 High grade spindle cell sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin
14 Osteosarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate
15 High grade spindle cell sarcoma Neoadjuvant and adjuvant Cisplatin, doxorubicin, methotrexate§
16 Osteosarcoma Adjuvant Cisplatin, doxorubicin
*Five of 12 cycles of methotrexate omitted due to complications.
†Randomized to vincristine, actinomycin D, ifosfamide as part of the EURO- EWING 99 study.10  
‡Randomized to vincristine, actinomycin D, cyclophosphamide as part of the EURO- EWING 99 study. 
§Methotrexate and cisplatin stopped at later cycles due to complications.
VAC, vincristine, actinomycin D, cyclophosphamide; VAI, vincristine, actinomycin D, ifosfamide; VIDE, vincristine, ifosfamide, doxorubicin, 
etoposide.
Fig. 1
CONsolidated Standards Of Reporting Trials (CONSORT) flow diagram. DFR, distal femoral arthroplasty; PACS, Picture Archiving and Communication System.
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growth was quantified by measuring the maximal length 
and thickness (millimetres) of the extracortical bone pedicle 
growing from the level of the shoulder of the HA collar in 
orthogonal regions (anterior (A), posterior (P), medial (M), 
and lateral (L)) surrounding the HA collar and implant shaft. 
On the radiographs, osseointegration was quantified by ex-
pressing the length (millimetres) of the extracortical bony 
pedicle in direct contact with the HA collar for each region 
(A, P, M, L) as a percentage of the full length (millimetres) 
of the collar. The overall osseointegration of the collar was 
calculated by taking the mean of the integration occurring 
in each plane. The presence of a gap between the shoulder 
of the HA collar and the transection site was observed and 
quantified in each region (A, P, M, L), with no gap being 
denoted as 0 mm. To evaluate loosening of the cemented 
intramedullary component the RLL score was calculated. 
The cement mantle surrounding the intramedullary com-
ponent is split into 12 equal zones, with six on either side 
of the component midline. A score of one is given if a zone 
contains a radiolucent line at the cement- bone interface 
suggesting loosening. This was done for both AP and later-
al radiographs, therefore the maximum RLL score that can 
be given for any DFR is 24.8 The assessor was blinded as to 
whether they were scoring the radiograph of a patient who 
had received or not received chemotherapy.
Statistical analysis. Statistical analysis was performed us-
ing SPSS Statistics V22 (IBM, Armonk, New York, USA). 
Data were tested for normality using the Shapiro- Wilk 
test and non- parametric data were compared using a 
Mann- Whitney U test. Multiple data comparisons for 
non- parametric data were compared using a Kruskal- 
Wallis test. Categorical data were compared using the 
chi- squared test. A p- value < 0.05 was considered to be 
significant. Correlation analysis was conducted using 
Pearson’s correlation coefficient with p < 0.05 being seen 
as significant. Regression analysis was performed using 
RLL as the dependent variable and age, sex, resection 
length, and whether or not they received chemotherapy 
as independent variables; those variables with a p- value < 
0.05 were seen as significant. The post hoc power analy-
sis was completed using the asymptotic relative efficien-
cy method on G*Power (v3.1.9.2; University of Kiel, Kiel, 
Germany) using an α-value of 0.05 for RLL only. A medi-
um effect size (d = 0.5) was used as defined by Cohen et 
al.13
Results
Lucent lines around DFRs, as measured in the RLL score, 
in chemotherapy patients significantly increased over 
the three- year period (p = 0.009, Kruskal- Wallis test). 
This suggests worsening radiological loosening of the 
intramedullary cemented component over the first three 
years. In contrast, no significant change in RLL score was 
observed in the non- chemotherapy group (p = 0.061, 
Kruskal- Wallis test). The disparity in RLL score between 
the two groups becomes greater over time, reaching 
statistical significance at year 3 (p = 0.044, Mann- Whitney 
U test) (Figure 3).
The median overall size of the gap seen in year 3 
(3.2 mm; interquartile range (IQR) 2.6 to 4.1; p < 0.001, 
Mann- Whitney U test) in the chemotherapy group was 
significantly greater than that found at year 1 (0.0 mm; 
IQR 0.0 to 7.0) and 2 (0.2 mm; IQR 0.0 to 1.0). There was 
no significant difference observed in the median overall 
gap size between year 1 (0.7 mm; IQR 0.4 to 1.7), year 2 
(0.6 mm; IQR 0.0 to 2.0), and year 3 (1.8 mm; IQR 0.1 to 
Table II. Comparisons of demographic data across chemotherapy and non- 
chemotherapy groups.
Variable Chemotherapy Non- chemotherapy p- value
Median age, yrs 
(IQR)
31 (19 to 50) 35 (29 to 44) 0.395*
Sex, male:female, n 9:7 9:9 0.566†
Median resection 
level, % (IQR)
39.5 (33.0 to 48.5) 26.2 (24.8 to 29.7) < 0.001*
*Mann- Whitney U test.
†Chi- squared test.
IQR, interquartile range.
Table III. Correlation analysis between variables with Pearson correlation 
coefficients and p- values.
Variable Measure Gap RLL Osseointegration
Resection length Correlation 
coefficient
-0.078 0.193 0.086








p- value 0.004* N/A N/A
*Statistically significant.
N/A, not applicable; RLL, radiolucent line.
Fig. 2
Anteroposterior (right) and lateral (left) radiographs of distal femoral 
arthroplasty intramedullary component showing the zones used for the 
radiolucent line score together with length, thickness, and gap distances 
measured around the hydroxyapatite (HA) collar. Radiolucent lines are 
evident in all zones in the lateral radiograph, giving a maximum score of 12.
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2.7) in the non- chemotherapy group. Subgroup analysis 
reveals a significant (p = 0.024, Kruskal- Wallis test) differ-
ence in the size of the gap at the medial aspect of the 
HA collar shoulder in the third year. Those undergoing 
chemotherapy have a median 3.2 mm (IQR 1.8 to 4.7) 
gap compared to a much smaller median 1.3 mm (IQR 
0.0 to 2.3) in the non- chemotherapy group. No statistical 
differences were detected in the anterior, posterior, and 
lateral gaps otherwise.
Significantly lower median osseointegration of the HA 
collar was observed posteriorly in those receiving chemo-
therapy (0.0%; IQR 0.0% to 0.0%) compared with those in 
the non- chemotherapy group (8.6%; IQR 0.0% to 37.9%; 
p = 0.021, Mann- Whitney U test) at three years, however 
no significant differences were observed anteriorly, medi-
ally, or laterally. A median overall increase in osseointe-
gration was observed in the non- chemotherapy group 
from year 1 (2.6%; IQR 0.0% to 15.2%), year 2 (11.4%; 
IQR 0.0% to 33.0%), and year 3 (12.8%; IQR 0.4% to 
30.1%), however this did not translate into a statistically 
significant result (p = 0.232, Kruskal- Wallis test).
Greater osseointegration of the HA collar was found 
to significantly negatively correlate with the RLL score. 
In contrast, gap formation suggesting osteolysis and 
RLL score were found to be significantly positively 
correlated. Resection length was found to not correlate 
with RLL score, gap formation, or osseointegration (Table 
III). Chemotherapy, sex, age, or resection length were 
not significant in predicting RLL score according to the 
regression analysis. Using our data, a post hoc power 
analysis reveals that our study was powered adequately.
Extracortical bone pedicles were found to develop 
around the HA collar in both groups. The length of the 
pedicles increased through from years 1 to 3 for the 
chemotherapy group, however this reached a peak in 
year 2 and was found to have resorbed slightly in year 
3 in the non- chemotherapy group. For both groups, the 
thickness of the bone pedicles peaked in year 2 before 
again showing resorption in year 3 (Table  IV). These 
observed differences did not translate into statistical 
differences between or within the groups.
Discussion
Limb salvage surgery remains the current gold standard 
for treatment of bone and soft tissue tumours, however 
endoprosthetic reconstruction remains fraught with 
complications with higher rates of aseptic loosening 
than standard primary arthroplasty procedures.5 A large 
proportion of these patients have chemotherapy and 
therefore it is possible that this may contribute to the 
higher rate of loosening.
Literature has shown the substantial effects of doxo-
rubicin, cisplatin, and ifosfamide on osteotomy healing 
and incorporation of cortical autografts, with histological 
evidence of poor new bone formation and decreased 
strength of healed osteotomies.6 A study evaluating 
cortical hypertrophy around the Compress distal femoral 
endoprosthesis (Biomet, Warsaw, Indiana, USA) showed 
greater hypertrophy around the implant in patients not 
receiving chemotherapy in the first postoperative year.14 
In contrast, Muscolo et al15 found that the use of chemo-
therapy did not have a significant effect on the overall 
allograft survival rates in patients undergoing reconstruc-
tion using osteoarticular allografts for musculoskeletal 
sarcomas. This is the first study to show that multidrug 
chemotherapy worsens radiological loosening of DFRs 
and reduces osseointegration.
A large gap as a result of osteolysis and the inhibition of 
bone formation at the shoulder of the implant will cause 
increased strain on the component leading to loosening.16 
The amount of strain and therefore loosening is dictated by 
the osseointegration of extracortical bone and the quality 
of the intramedullary component fixation. It is important 
Fig. 3
Boxplot of radiolucent line scores for non- chemotherapy and chemotherapy 
groups over time. p = 0.044, Mann- Whitney U test.
Table IV. A comparison of bone pedicle size growing around the 
hydroxyapatite collar in the chemotherapy and non- chemotherapy groups 
over the first three postoperative years.
Group Variable Year 1 Year 2 Year 3
Non- chemo Median pedicle length, 
mm (IQR)












1.9 (1.0 to 
3.8)
Chemo Median pedicle length, 
mm (IQR)
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to consider both the gap size and RLL score when assessing 
implant loosening radiologically. DFRs in chemotherapy 
patients show a greater gap formation and higher RLL 
score than subjects in the control group. These two indi-
cators of radiological loosening are furthermore positively 
correlated. Finite element analysis has shown osseointegra-
tion of extracortical bone reduces stresses passing through 
the component of the implant;7,17 our study supports this 
as radiological loosening of the intramedullary compo-
nent is negatively correlated with osseointegration of the 
extracortical bone. This indicates that the stresses along the 
component due to poor integration at the shoulder may 
result in the formation of radiolucent lines.
Osseointegration of extracortical bone in DFRs has 
been shown to be effective in reducing loosening.18 Our 
study has shown that patients undergoing multidrug 
chemotherapy show reduced rates of osseointegration, 
together with greater radiological loosening in the initial 
postoperative years following reconstruction.
Bone integration can be described on a cellular level 
by the attachment of osteoblasts onto the implant 
surface and subsequent extracellular mineralization. 
Osteoblasts attach to substrates using integrins.19 One 
of the most important extracellular matrix proteins that 
integrins attach to is fibronectin, of which human blood 
plasma levels reduce significantly when patients receive 
chemotherapy. These reduced levels can be seen as early 
as the next day following chemotherapy,20 with up to a 
50% reduction in levels seen over three weeks from the 
initiation of chemotherapy.21 Treatment with cisplatin 
has been shown to directly reduce gene expression of 
fibronectin by almost 2.5 times.22 Reduced osseointegra-
tion of HA collars in patients undergoing chemotherapy 
could therefore be due to the negative effect of chemo-
therapy on cell attachment.
There was no difference in the amount of ECBB from 
the transection site over the HA collar between the chemo-
therapy and non- chemotherapy groups, indicating that 
bone formation was not impaired by chemotherapy. 
Evidence also exists which has conversely shown bone 
turnover to be clearly affected by the use of chemo-
therapy.6 Avedian et al14 found chemotherapy to tempo-
rarily adversely affect bone growth at the bone- implant 
interface, however after one year they observed no differ-
ences between the two groups. Either chemotherapy has 
no true effect on extracortical bone growth, or the three- 
year follow- up period in our study is not long enough to 
detect the difference in ECBB between the two groups. 
Increased strain at the HA collar region due to early loos-
ening can itself stimulate bone growth without the ability 
to osseointegrate, much like callus formation in the hyper-
trophic nonunion scenario where there is failed continuity 
of callus between the fragments. This may counteract the 
inhibition of bone growth due to the chemotherapy.
There was a significant difference in resection length 
between the two groups. In our study, resection length 
did not correlate with RLL score, osseointegration, and 
gap formation, nor was it a significant variable in our 
regression analysis. This suggested that it was not a 
potential confounding factor according to our data. The 
sample size is small with a large number of exclusions. 
This was to keep the groups as homogenous as possible 
and to exclude other factors that may affect bone growth 
at the HA collar. Osseointegration was quantified as 
radiological contact between pedicle and collar. True 
osseointegration can only be confirmed histologically, 
which has already been proven for this collar design in a 
previous study.8 Finally, the control group is very homog-
enous with all the cases being of patients with giant cell 
tumours; the same cannot be said for the chemotherapy 
group. However, the chemotherapeutic agents received 
by these patients were very similar and therefore we do 
not believe this limited our results greatly.
In conclusion, this is the first study to evaluate the 
effect of multidrug chemotherapy on radiological signs of 
loosening around endoprostheses. We cannot guarantee 
the findings in our study are due to the chemotherapy 
alone and not the underlying sarcoma, however it is likely 
that chemotherapy does affect implant fixation given the 
in vivo evidence from animal models, which have shown 
that such treatment disrupts bone formation.23–25 An 
understanding of the involvement of multidrug chemo-
therapy on the early osseointegration and loosening 
of endoprostheses is imperative to allow for continued 
development of limb salvage procedures. This is crucial, 
particularly with emerging technologies used to improve 
osseointegration of endoprostheses.26 We demonstrated 
that there are radiological signs of loosening as early as 
three years postoperatively, and differences in osseointe-
gration of the HA collar were observed in the first post-
operative year. We recommend that bone tumour units 
provide stringent follow- up to those patients receiving 
chemotherapy, particularly in the initial years postoper-
atively. Studies with longer follow- up of this cohort of 
patients must be performed to conclude whether these 
radiological findings lead to clinical symptomatic loos-
ening or implant failure.
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